Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 14.62%.

  • Lifecore Biomedical, Inc. \De\'s EBIT Margin rose 89400.0% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was 13.38%, marking a year-over-year decrease of 64900.0%. This contributed to the annual value of 13.38% for FY2025, which is 64900.0% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its EBIT Margin stood at 14.62% for Q2 2025, which was up 89400.0% from 25.68% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s EBIT Margin's 5-year high stood at 14.62% during Q2 2025, with a 5-year trough of 46.89% in Q3 2024.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s EBIT Margin had a median value of 11.56% in 2022 and averaged 12.51%.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s EBIT Margin soared by 278400bps in 2021 and then crashed by -388900bps in 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBIT Margin (Quarter) stood at 14.41% in 2021, then crashed by -270bps to 24.48% in 2022, then surged by 80bps to 4.92% in 2023, then fell by -22bps to 6.02% in 2024, then surged by 343bps to 14.62% in 2025.
  • Its last three reported values are 14.62% in Q2 2025, 25.68% for Q1 2025, and 6.02% during Q4 2024.